Tofersen: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 11, p. 1039, doi. 10.1007/s40265-023-01904-6
- By:
- Publication type:
- Article
Works matching IS 00126667 AND DT 2023 AND VI 83 AND IP 11
Results: 11
1
2
Neuropathic Pain and Spinal Cord Injury: Management, Phenotypes, and Biomarkers.
- Published in:
- Drugs, 2023, v. 83, n. 11, p. 1001, doi. 10.1007/s40265-023-01903-7
- By:
- Publication type:
- Article
3
Focus on Metformin: Its Role and Safety in Pregnancy and Beyond.
- Published in:
- Drugs, 2023, v. 83, n. 11, p. 985, doi. 10.1007/s40265-023-01899-0
- By:
- Publication type:
- Article
4
Might It Be Appropriate to Anticipate the Use of Long-Acting Muscarinic Antagonists in Asthma?
- Published in:
- Drugs, 2023, v. 83, n. 11, p. 957, doi. 10.1007/s40265-023-01897-2
- By:
- Publication type:
- Article
5
Correction to: Zavegepant: First Approval.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
6
Effectiveness of Non-Budesonide Therapies in Management of Microscopic Colitis: A Systematic Review and Meta-analysis.
- Published in:
- Drugs, 2023, v. 83, n. 11, p. 1027, doi. 10.1007/s40265-023-01914-4
- By:
- Publication type:
- Article
7
Concizumab: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 11, p. 1053, doi. 10.1007/s40265-023-01912-6
- By:
- Publication type:
- Article
8
Mirikizumab: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 11, p. 1045, doi. 10.1007/s40265-023-01909-1
- By:
- Publication type:
- Article
9
Correction to: Lenacapavir: First Approval.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
10
Correction to: Comment on: 'Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know?'.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
11
Extended and Continuous Infusion of Novel Protected β-Lactam Antibiotics: A Narrative Review.
- Published in:
- Drugs, 2023, v. 83, n. 11, p. 967, doi. 10.1007/s40265-023-01893-6
- By:
- Publication type:
- Article